1599-5453 Contact Us KO
Autonomic Medicine

Raynaud's Syndrome

Raynaud's Syndrome · I73.0

Raynaud's syndrome overview: primary vs secondary types, pathophysiology of vasospastic episodes, triggers, diagnostic criteria, and management including stellate ganglion block.

2026-03-28

At a Glance

Raynaud's syndrome overview: primary vs secondary types, pathophysiology of vasospastic episodes, triggers, diagnostic criteria, and management including stellate ganglion block.

Definition and Overview

Raynaud syndrome is a condition in which excessive vasospasm occurs in peripheral arteries and arterioles in response to cold or emotional stress [1]. The fingers are most commonly affected, though the toes, ears, nose, and lips may also be involved.

It affects approximately 3–5% of the global population and is approximately 5–9 times more common in women than men [3]. It is particularly common in young women aged 15–30 [3]. It is classified into primary Raynaud phenomenon (formerly "Raynaud disease") and secondary Raynaud phenomenon associated with an underlying disease.

Triphasic Color Changes

The triphasic color change of the skin during a Raynaud attack is characteristic [1].

Pallor: The affected area turns white as vasospasm interrupts local blood flow. Cyanosis: Stagnant blood with reduced oxygen saturation causes a blue discoloration. Erythema (rubor): As the vasospasm resolves, blood rushes back in, causing the area to turn red and warm. Burning pain may accompany the recovery phase.

Not all three phases may be clearly present in every patient; biphasic changes from pallor directly to erythema are also common.

Pathogenesis

The pathogenesis of Raynaud syndrome is multifactorial [2].

Sympathetic overactivation and alpha-2 receptor hypersensitivity are central. Upon cold exposure, norepinephrine is released from sympathetic nerve terminals, and alpha-2C receptors on vascular smooth muscle recognize this signal and induce vasoconstriction. In Raynaud patients, these receptors are hypersensitive or overexpressed [2]. A mechanism of increased alpha-2C receptor translocation to the cell surface in cold environments has also been confirmed [2].

Endothelial dysfunction is also involved. Production of vasodilators such as nitric oxide (NO) and prostacyclin is reduced, while secretion of vasoconstrictors (endothelin-1) is increased, resulting in impaired vasodilatory capacity [2].

In secondary Raynaud phenomenon, structural vascular damage from autoimmune mechanisms additionally contributes. In systemic sclerosis, endothelial cell damage and vascular wall fibrosis lead to structural vascular narrowing in addition to functional vasospasm [3].

Primary vs. Secondary Differentiation

Underlying conditions causing secondary Raynaud phenomenon include connective tissue diseases (systemic sclerosis, systemic lupus erythematosus, mixed connective tissue disease, rheumatoid arthritis, Sjogren syndrome), occupational factors (vibrating tool use, repetitive trauma), medications (beta-blockers, ergotamine, chemotherapy agents), vascular occlusive diseases (thrombosis, atherosclerosis), endocrine disorders (hypothyroidism), and neurological disorders [3].

Helpful diagnostic tests include nailfold capillaroscopy, antinuclear antibodies (ANA), anti-CCP antibodies, complement levels, rheumatoid factor, and complete blood count [1]. Abnormal capillaries (dilated, absent, hemorrhagic) on nailfold capillaroscopy suggest an association with connective tissue disease.

Treatment

Non-pharmacological Treatment

Keeping warm is the most fundamental measure. Exposure to cold environments should be minimized, and thick gloves and hand warmers should be used. Keeping the whole body warm is more effective than warming only the fingers. Smoking cessation is important, as nicotine constricts blood vessels and can trigger or worsen Raynaud attacks. Relaxation therapy, biofeedback, and cognitive behavioral therapy for stress management may provide additional benefit.

Pharmacological Treatment

Calcium channel blockers are the first-line medication. Meta-analyses have reported that long-acting dihydropyridine calcium channel blockers such as amlodipine and nifedipine reduce Raynaud attack frequency by approximately 30–40% [4].

In secondary Raynaud phenomenon with digital ulcers or high risk, phosphodiesterase-5 inhibitors (sildenafil), intravenous prostacyclin (iloprost), and endothelin receptor antagonists (bosentan) are used [3].

Sympathetic blockade (stellate ganglion block, digital sympathectomy) is attempted for vasospasm control in severe secondary Raynaud phenomenon.

Frequently Asked Questions

Raynaud syndrome is a condition in which blood vessels in the fingers (or toes) constrict excessively in response to cold weather or emotional stress, reducing blood supply. The skin color changes from white to blue to red, with numbness and pain that resolve upon warming. Unlike simply having cold or numb fingers, the distinctive color change is characteristic. It is most common in young women, and most cases are primary (without underlying disease), though some are associated with underlying conditions.

Excessive activation of the sympathetic nervous system, which constricts blood vessels, is the core mechanism of Raynaud syndrome. In response to cold or stress stimuli, vasoconstriction occurs far more intensely than normal. Norepinephrine released from sympathetic nerve terminals stimulates alpha-2 receptors on vascular smooth muscle, and in Raynaud patients, these receptors are hypersensitive or overexpressed. Autonomic function testing may confirm a pattern of sympathetic overactivation.

Primary Raynaud (Raynaud disease) occurs without underlying disease and has a good prognosis. It is characterized by onset before age 40, bilateral symmetry, absence of ischemic complications (ulcers, gangrene), negative ANA, and normal nailfold capillaroscopy. Secondary Raynaud is associated with underlying diseases and is common in systemic sclerosis, lupus, rheumatoid arthritis, and Sjogren syndrome. It is distinguished by later onset, asymmetry, digital ulcers, positive ANA, and abnormal capillaroscopy findings.

Lifestyle management is fundamental. Keeping warm (thick gloves, hand warmers), smoking cessation, stress management, and limiting excessive caffeine intake are helpful. When lifestyle measures are insufficient, calcium channel blockers (amlodipine, nifedipine) are used, with studies showing attack frequency reduction in approximately one-third of patients. In secondary cases, phosphodiesterase inhibitors such as sildenafil or prostacyclins such as iloprost may be used to prevent digital ulcers.

If only primary Raynaud phenomenon is present, it may cause lifestyle inconvenience but rarely leads to digital ulcers or tissue damage, making it relatively low risk. However, secondary Raynaud phenomenon depends on the underlying disease. Particularly in patients with systemic sclerosis, Raynaud phenomenon can lead to digital ischemic ulcers, gangrene, and non-healing wounds, requiring aggressive treatment. If Raynaud symptoms appear for the first time, specialist evaluation is essential to rule out secondary causes.

Yes, psychological stress is an important trigger for Raynaud attacks. During stress, sympathetic activity increases, intensifying peripheral vasoconstriction. Raynaud attacks triggered by emotional stress produce the same vascular response as cold stimulation of the fingers. Research suggests that stress management, relaxation therapy, and biofeedback may help reduce the frequency of Raynaud attacks.

References

  1. [1] Wigley FM, Flavahan NA (2016). "Raynaud's phenomenon." New England Journal of Medicine, 375: 556-565. DOI PubMed
  2. [2] Flavahan NA (2015). "A vascular mechanistic approach to understanding Raynaud phenomenon." Nature Reviews Rheumatology, 11: 146-158. DOI PubMed
  3. [3] Herrick AL (2012). "The pathogenesis, diagnosis and treatment of Raynaud phenomenon." Nature Reviews Rheumatology, 8: 469-479. DOI PubMed
  4. [4] Thompson AE, Pope JE (2005). "Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis." Rheumatology, 44: 145-150. DOI PubMed
  5. [5] Pauling JD, Hughes M, Pope JE (2019). "Raynaud's phenomenon—an under-appreciated compositional factor in fibromyalgia?." Clinical Rheumatology, 38: 1695-1697. DOI PubMed

Related Articles

Stress and the Autonomic Nervous System
Raynaud SyndromeRaynaud PhenomenonRaynaud DiseaseFinger Color ChangePeripheral VasospasmSympathetic Vascular

This content is provided for informational purposes only and is not a substitute for professional medical advice. If you have symptoms, please consult a qualified physician.

Are you experiencing related symptoms?

Get an accurate diagnosis at OSANG Neurosurgery.

02-514-8887 KakaoTalk Consultation